RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$33.61

05 Dec
2022

-0.490

OPEN

$34.20

-1.44%

HIGH

$34.27

1,425,051

LOW

$33.56

TARGET
$36.625 9.0% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . NAN . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . PEB . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY23
Forecast
FY24
Forecast
EPS (cps) 93.2 xxx
DPS (cps) 25.5 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 36.1 xxx
Dividend Yield 0.8% xxx
Div Pay Ratio(%) 27.4% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.14%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.74

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 09/11 - ex-div 4.73c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx73.6
DPS All xxxxxxxxxxxxxxx16.5
Sales/Revenue xxxxxxxxxxxxxxx4,934.0 M
Book Value Per Share xxxxxxxxxxxxxxx333.8
Net Operating Cash Flow xxxxxxxxxxxxxxx484.2 M
Net Profit Margin xxxxxxxxxxxxxxx21.78 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx24.62 %
Return on Invested Capital xxxxxxxxxxxxxxx19.49 %
Return on Assets xxxxxxxxxxxxxxx15.68 %
Return on Equity xxxxxxxxxxxxxxx24.62 %
Return on Total Capital xxxxxxxxxxxxxxx24.80 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-40.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

31/10/2022

1

Outperform

$37.50

11.57%

While ResMed reported strength in card-to-cloud uptake in the US during the first quarter, up 23%, a -10% decline from the rest of world saw the company miss consensus net profit estimates by -2%. 

Credit Suisse attributes the weaker result partially to supply constraints, and highlights it will take longer for the backlog to be filled with demand continuing to outstrip supply. The broker retains its medium-term view, believing the market continues to underestimate the longer-term benefit to ResMed from the Philips recall. 

The Outperform rating is retained and the target price decreases to $37.50 from $40.00.

FORECAST
Credit Suisse forecasts a full year FY23 dividend of 25.49 cents and EPS of 91.98 cents.
Credit Suisse forecasts a full year FY24 dividend of 26.64 cents and EPS of 109.12 cents.

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

RMD STOCK CHART